Last edition
News about "NRG1 fusion targeted therapy"
Partner Therapeutics Submits sBLA to FDA for BIZENGRI
Partner Therapeutics submits sBLA to FDA for BIZENGRI in NRG1 fusion-positive cholangiocarcinoma, supported by eNRGy study data showing 36.8 percent response rate and durable efficacy.
NRG1 Fusion Targeted Therapy | 15/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members